Advertisement
Home 2017

Yearly Archives: 2017

October 2017 Briefing – Cosmetic Surgery

0
Here are what the editors at HealthDay consider to be the most important developments in Cosmetic Surgery for October 2017. This roundup includes the...

October 2017 Briefing – Anesthesiology

0
Here are what the editors at HealthDay consider to be the most important developments in Anesthesiology for October 2017. This roundup includes the latest...

October 2017 Briefing – Nephrology

0
Here are what the editors at HealthDay consider to be the most important developments in Nephrology for October 2017. This roundup includes the latest...

October 2017 Briefing – Radiology

0
Here are what the editors at HealthDay consider to be the most important developments in Radiology for October 2017. This roundup includes the latest...

October 2017 Briefing – Pathology

0
Here are what the editors at HealthDay consider to be the most important developments in Pathology for October 2017. This roundup includes the latest...

October 2017 Briefing – Allergy

0
Here are what the editors at HealthDay consider to be the most important developments in Allergy for October 2017. This roundup includes the latest...
Calquence (acalabrutinib) has been approved by the U.S. Food and Drug Administration to treat adults with mantle cell lymphoma.

Calquence Approved for Mantle Cell Lymphoma

0
For patients who have not responded to at least one prior treatment or who have relapsed
Fentanyl was involved in more than half of opioid overdose deaths reported in the second half of 2016

Fentanyl or Analogs Tied to More Than Half of All Opioid Deaths

0
And 57 percent of fentanyl-related deaths also tested positive for other drugs, such as heroin
Percutaneous coronary intervention (PCI) of the culprit lesion is associated with better 30-day outcomes than immediate multivessel PCI among patients with multivessel coronary artery disease and acute myocardial infarction with cardiogenic shock

Culprit-Lesion-Only PCI Tied to Improved 30-Day Outcomes

0
Linked to lower risk of mortality compared to multivessel PCI in patients with acute MI and multivessel CAD
Rates of systemic lupus erythematosus (SLE) mortality have decreased since 1968 but are still higher than non-SLE mortality

Systemic Lupus Erythematosus Mortality Down Since 1968

0
However, SLE mortality is still higher than non-SLE mortality; sex, racial, regional disparities exist